Stocktoria
Arcturus Therapeutics Holdings Inc. ARCT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-05-22
Arcturus Therapeutics Holdings Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -93.0% | -62.8% | -46.9% | 5.9% | -1641.3% |
| Net margin | -80.2% | -53.1% | -17.8% | 4.5% | -1648.0% |
| FCF margin | -90.8% | -39.7% | -12.6% | 11.8% | -1120.2% |
| Return on assets | -24.3% | -23.5% | -6.9% | 2.1% | -51.8% |
| Return on equity | -30.7% | -33.6% | -10.7% | 3.5% | -89.2% |
| Debt / equity | — | — | — | — | 0.18× |
| Current ratio | 6.64 | 4.67 | 4.72 | 3.18 | 3.81 |
| Revenue growth | -46.1% | -8.7% | -19.0% | 1566.8% | 29.6% |
Source: SEC EDGAR filings · CIK 0001768224 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.